Abstract
Eosinophilia is common in patients with type 2 inflammatory diseases, including atopic dermatitis (AD), asthma, and allergic rhinitis. This post hoc analysis assessed the effects of abrocitinib and dupilumab on eosinophilia in patients with moderate-to-severe AD, with or without comorbid asthma or allergic rhinitis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
